Checkpoint Therapeutics Stock Performance
| CKPT Stock | USD 3.75 0.28 8.07% |
On a scale of 0 to 100, Checkpoint Therapeutics holds a performance score of 17. The firm shows a Beta (market volatility) of 0.17, which signifies not very significant fluctuations relative to the market. As returns on the market increase, Checkpoint Therapeutics' returns are expected to increase less than the market. However, during the bear market, the loss of holding Checkpoint Therapeutics is expected to be smaller as well. Please check Checkpoint Therapeutics' standard deviation, expected short fall, period momentum indicator, as well as the relationship between the maximum drawdown and rate of daily change , to make a quick decision on whether Checkpoint Therapeutics' price patterns will revert.
Risk-Adjusted Performance
17 of 100
Weak | Strong |
Solid
Compared to the overall equity markets, risk-adjusted returns on investments in Checkpoint Therapeutics are ranked lower than 17 (%) of all global equities and portfolios over the last 90 days. In spite of comparatively unfluctuating basic indicators, Checkpoint Therapeutics unveiled solid returns over the last few months and may actually be approaching a breakup point. ...more
Actual Historical Performance (%)
One Day Return 13.51 | Five Day Return 25.54 | Year To Date Return 94.32 | Ten Year Return (91.49) | All Time Return (91.49) |
Last Split Factor 1:10 | Last Split Date 2022-12-06 |
1 | HC Wainwright Reaffirms Buy Rating for Checkpoint Therapeutics - MarketBeat | 09/17/2024 |
2 | Acquisition by Fortress Biotech, Inc. of 146341 shares of Checkpoint Therapeutics subject to Rule 16b-3 | 09/27/2024 |
3 | Acquisition by Herskowitz Neil of 16502 shares of Checkpoint Therapeutics subject to Rule 16b-3 | 10/23/2024 |
4 | Checkpoint Therapeutics stock hits 52-week high at 3.62 - Investing.com | 10/24/2024 |
5 | Acquisition by Rosenwald Lindsay A Md of 32051 shares of Checkpoint Therapeutics subject to Rule 16b-3 | 11/08/2024 |
6 | Checkpoint Therapeutics Issues Quarterly Earnings Results, Misses Estimates By 0.08 EPS | 11/13/2024 |
7 | Acquisition by Weiss Michael S of 50000 shares of Checkpoint Therapeutics subject to Rule 16b-3 | 11/15/2024 |
| Begin Period Cash Flow | 12.1 M |
Checkpoint |
Checkpoint Therapeutics Relative Risk vs. Return Landscape
If you would invest 225.00 in Checkpoint Therapeutics on August 27, 2024 and sell it today you would earn a total of 150.00 from holding Checkpoint Therapeutics or generate 66.67% return on investment over 90 days. Checkpoint Therapeutics is currently generating 0.8798% in daily expected returns and assumes 4.0071% risk (volatility on return distribution) over the 90 days horizon. In different words, 35% of stocks are less volatile than Checkpoint, and 83% of all traded equity instruments are projected to make higher returns than the company over the 90 days investment horizon. Expected Return |
| Risk |
Checkpoint Therapeutics Market Risk Analysis
Today, many novice investors tend to focus exclusively on investment returns with little concern for Checkpoint Therapeutics' investment risk. Standard deviation is the most common way to measure market volatility of stocks, such as Checkpoint Therapeutics, and traders can use it to determine the average amount a Checkpoint Therapeutics' price has deviated from the expected return over a period of time. It is calculated by determining the expected price for the established period and then subtracting this figure from each price point. The differences are then squared, summed, and averaged to produce the variance.
Sharpe Ratio = 0.2196
| Best Portfolio | Best Equity | |||
| Good Returns | ||||
| Average Returns | ||||
| Small Returns | CKPT | |||
| Cash | Small Risk | Average Risk | High Risk | Huge Risk |
| Negative Returns |
Estimated Market Risk
| 4.01 actual daily | 35 65% of assets are more volatile |
Expected Return
| 0.88 actual daily | 17 83% of assets have higher returns |
Risk-Adjusted Return
| 0.22 actual daily | 17 83% of assets perform better |
Based on monthly moving average Checkpoint Therapeutics is performing at about 17% of its full potential. If added to a well diversified portfolio the total return can be enhanced and market risk can be reduced. You can increase risk-adjusted return of Checkpoint Therapeutics by adding it to a well-diversified portfolio.
Checkpoint Therapeutics Fundamentals Growth
Checkpoint Stock prices reflect investors' perceptions of the future prospects and financial health of Checkpoint Therapeutics, and Checkpoint Therapeutics fundamentals are critical determinants of its market performance. Overall, investors pay close attention to revenue and earnings growth, profit margins, and debt levels. These fundamentals can have a significant impact on Checkpoint Stock performance.
| Return On Equity | -12.2 | ||||
| Return On Asset | -3.17 | ||||
| Operating Margin | (162.76) % | ||||
| Current Valuation | 178.42 M | ||||
| Shares Outstanding | 48.13 M | ||||
| Price To Earning | (7.60) X | ||||
| Price To Book | 8.56 X | ||||
| Price To Sales | 2,348 X | ||||
| Revenue | 103 K | ||||
| Gross Profit | (48.19 M) | ||||
| EBITDA | (52.15 M) | ||||
| Net Income | (51.85 M) | ||||
| Cash And Equivalents | 30.89 M | ||||
| Cash Per Share | 0.33 X | ||||
| Total Debt | 18.43 M | ||||
| Debt To Equity | 0.1 % | ||||
| Current Ratio | 1.30 X | ||||
| Book Value Per Share | (0.47) X | ||||
| Cash Flow From Operations | (47.59 M) | ||||
| Earnings Per Share | (1.83) X | ||||
| Market Capitalization | 183.12 M | ||||
| Total Asset | 5.38 M | ||||
| Retained Earnings | (314.33 M) | ||||
| Working Capital | (13.05 M) | ||||
| Current Asset | 46.85 M | ||||
| Current Liabilities | 2.89 M | ||||
About Checkpoint Therapeutics Performance
Assessing Checkpoint Therapeutics' fundamental ratios provides investors with valuable insights into Checkpoint Therapeutics' financial health and overall profitability. This information is crucial for making informed investment decisions. A high ROA would indicate that the Checkpoint Therapeutics is effectively leveraging its assets and equity to generate significant profits, making it an appealing investment. Conversely, low Return on Assets could signal underlying management issues in assets and equity, indicating a necessity for operational refinements. Please also refer to our technical analysis and fundamental analysis pages.
| Last Reported | Projected for Next Year | ||
| Return On Tangible Assets | (9.64) | (9.16) | |
| Return On Capital Employed | 4.00 | 4.20 | |
| Return On Assets | (9.64) | (9.16) | |
| Return On Equity | 3.97 | 4.17 |
Things to note about Checkpoint Therapeutics performance evaluation
Checking the ongoing alerts about Checkpoint Therapeutics for important developments is a great way to find new opportunities for your next move. Stock alerts and notifications screener for Checkpoint Therapeutics help investors to be notified of important events, changes in technical or fundamental conditions, and significant headlines that can affect investment decisions.| Checkpoint Therapeutics appears to be risky and price may revert if volatility continues | |
| The company reported the previous year's revenue of 103 K. Net Loss for the year was (51.85 M) with loss before overhead, payroll, taxes, and interest of (48.19 M). | |
| Checkpoint Therapeutics currently holds about 30.89 M in cash with (47.59 M) of positive cash flow from operations. This results in cash-per-share (CPS) ratio of 0.33. | |
| Checkpoint Therapeutics has a poor financial position based on the latest SEC disclosures | |
| Roughly 16.0% of the company shares are held by company insiders | |
| Latest headline from thelincolnianonline.com: Checkpoint Therapeutics Issues Quarterly Earnings Results, Misses Estimates By 0.08 EPS |
- Analyzing Checkpoint Therapeutics' financial statements, including its income statement, balance sheet, and cash flow statement, helps in understanding its overall financial health and growth potential.
- Getting a closer look at valuation ratios like price-to-earnings (P/E) ratio, price-to-sales (P/S) ratio, and price-to-book (P/B) ratio help in understanding whether Checkpoint Therapeutics' stock is overvalued or undervalued compared to its peers.
- Examining Checkpoint Therapeutics' industry or sector and how it is performing can give you an idea of its growth potential and how it is positioned relative to its competitors.
- Evaluating Checkpoint Therapeutics' management team can have a significant impact on its success or failure. Reviewing the track record and experience of Checkpoint Therapeutics' management team can help you assess the Company's leadership.
- Pay attention to analyst opinions and ratings of Checkpoint Therapeutics' stock. These opinions can provide insight into Checkpoint Therapeutics' potential for growth and whether the stock is currently undervalued or overvalued.
Additional Tools for Checkpoint Stock Analysis
When running Checkpoint Therapeutics' price analysis, check to measure Checkpoint Therapeutics' market volatility, profitability, liquidity, solvency, efficiency, growth potential, financial leverage, and other vital indicators. We have many different tools that can be utilized to determine how healthy Checkpoint Therapeutics is operating at the current time. Most of Checkpoint Therapeutics' value examination focuses on studying past and present price action to predict the probability of Checkpoint Therapeutics' future price movements. You can analyze the entity against its peers and the financial market as a whole to determine factors that move Checkpoint Therapeutics' price. Additionally, you may evaluate how the addition of Checkpoint Therapeutics to your portfolios can decrease your overall portfolio volatility.